• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Ovarian Cancer Drug Pipeline Update 2015

  • ID: 1196705
  • January 2015
  • Region: Global
  • Bioseeker

With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for existing and pipeline drugs.

There are today 257 companies plus partners developing 348 drugs targeting ovarian cancer in development. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 117 drugs. Ovarian Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 268 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 259 out of the 262 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 66 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.


Note: Product cover images may vary from those shown

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Almac Diagnostics Group Pfizer, Inc. Astrazeneca PLC Hologic Corporation Roche Diagnostics Ltd. Bristol-Myers Squibb